Tertiary Nav - Press Releases Press ReleasesMedia Statements Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Date Title 10/31/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 10/26/22 Sarepta Therapeutics anuncia los beneficiarios de la Entrega Inaugural de Subvenciones para LGMD; el programa apoya los esfuerzos innovadores para acortar el recorrido hasta el diagnóstico 10/26/22 Sarepta Therapeutics Announces Recipients of Inaugural LGMD Grant Awards; Program Supports Innovative Efforts to Shorten the Diagnostic Journey 10/26/22 Sarepta Therapeutics to Announce Third Quarter 2022 Financial Results 10/7/22 Sarepta Therapeutics Presents New Data from its Gene Therapy and RNA Platforms at World Muscle Society 2022 9/30/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 9/29/22 Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy 9/14/22 Sarepta Therapeutics Prices $1.0 Billion of Convertible Senior Notes Due 2027 9/12/22 Sarepta Therapeutics Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes Due 2027 9/7/22 Sarepta Therapeutics Anuncia a los Destinatarios de Route 79, el Programa de Becas de Duchenne, para el Año Académico 2022-2023 Pagination First page « first Previous page ‹ previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page next › Last page last » Displaying 61 - 70 of 812 Toolkit Print Page | Email Alerts | RSS Feeds | Contacts
Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Date Title 10/31/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 10/26/22 Sarepta Therapeutics anuncia los beneficiarios de la Entrega Inaugural de Subvenciones para LGMD; el programa apoya los esfuerzos innovadores para acortar el recorrido hasta el diagnóstico 10/26/22 Sarepta Therapeutics Announces Recipients of Inaugural LGMD Grant Awards; Program Supports Innovative Efforts to Shorten the Diagnostic Journey 10/26/22 Sarepta Therapeutics to Announce Third Quarter 2022 Financial Results 10/7/22 Sarepta Therapeutics Presents New Data from its Gene Therapy and RNA Platforms at World Muscle Society 2022 9/30/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 9/29/22 Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy 9/14/22 Sarepta Therapeutics Prices $1.0 Billion of Convertible Senior Notes Due 2027 9/12/22 Sarepta Therapeutics Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes Due 2027 9/7/22 Sarepta Therapeutics Anuncia a los Destinatarios de Route 79, el Programa de Becas de Duchenne, para el Año Académico 2022-2023 Pagination First page « first Previous page ‹ previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page next › Last page last » Displaying 61 - 70 of 812